Biopharma PEG Launches New Plant-Derived Cholesterol & DSPE for LNPs

Biopharma PEG recently announced the launch of a new plant-derived cholesterol & DSPE pharmaceutical ingredient that can be used in lipid nanoparticle (LNP) drug delivery systems.

These breakthrough ingredients are the result of years of research and development by Biopharma PEG, a cutting-edge company based in USA that manufactures and markets PEG derivatives for the pharmaceutical industry.

A product director from Biopharma PEG said: “We are delighted to bring this new plant-derived cholesterol and DSPE pharmaceutical ingredient to the market. Over the past year, the demand for lipids (including cholesterol & DSPE) has far outstripped supply. We have responded quickly to this market demand by adding a new production line to meet the growing demand for cholesterol in pharmaceutical liposomal drug delivery”.

Cholesterol from Biopharma PEG is derived from plants and is an innovative alternative to traditional cholesterol-derived products commonly used in the pharmaceutical industry. Most of the cholesterol currently available on the market is extracted from animal brains and lanolin, all of which are derived from animals. Plant-derived cholesterol eliminates people's concerns about the risk of animal-derived cholesterol carrying animal viruses, and broadens its use in the pharmaceutical, cosmetic, and health food industries.

The DSPE from Biopharma PEG is the starting material of mPEG-DSPE, which is a PEG-based phospholipid  can be used to synthesize liposomes for delivering cancer agents.

If you’re interested in incorporating these innovative new ingredients into your LNP formulations, keep an eye out for products that contain them.

About us

Biopharma PEG Scientific Inc. is a biotechnology-oriented company in Watertown, Massachusetts. We are dedicated to manufacturing and supplying high-purity PEG derivatives, and helper lipids such as Cholesterol & DSPE to customers worldwide to meet new drug delivery goals. We continuously expand the capability to manufacture high-purity pharmaceutical excipients for lipid nanoparticles in both non-GMP and GMP grades.